Skip to main content

Therapeutic Effect of Lactobacillus acidophilus-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome

Abstract

Probiotic bacteria exhibit a variety of properties, which are unique to a particular strain. Lactobacillus acidophilus-SDC 2012, 2013 are new strains isolated from Korean infants’ feces. The potential utility of Lactobacillus acidophilus-SDC 2012, 2013 in irritable bowel syndrome (IBS) was studied. Forty IBS patients were randomized into a placebo (n = 20) and probiotics group (n = 20). Four weeks of treatment with L. acidophilus-SDC 2012, 2013 was associated with a reduced score for abdominal pain or discomfort compared to the baseline (P = 0.011). The percent reduction in abdominal pain or discomfort exceeded the placebo scores by more than 20% (23.8 and 0.2% for probiotics and placebo, respectively, P = 0.003). There was a significant difference in the proportion of responders between the probiotics and placebo groups (P = 0.011). There was no drop out or adverse events for either group during the study period. Lactobacillus acidophilus-SDC 2012, 2013 appeared to have a beneficial effect in patients with IBS. Further studies are warranted.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Schrezenmeir J, de Vrese M (2001) Probiotics, prebiotics, and synbiotics–approaching a definition. Am J Clin Nutr 73:361S–364S

    PubMed  CAS  Google Scholar 

  2. 2.

    Floch MH, Madsen KK, Jenkins DJ, Guandalini S, Katz JA, Onderdonk A, Walker WA, Fedorak RN, Camilleri M (2006) Recommendations for probiotic use. J Clin Gastroenterol 40:275–278

    PubMed  Article  Google Scholar 

  3. 3.

    Quigley EM, Flourie B (2007) Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 19:166–172

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B (2000) Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95:1231–1238

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Niedzielin K, Kordecki H, Birkenfeld B (2001) A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 13:1143–1147

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17:895–904

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541–551

    PubMed  Article  Google Scholar 

  8. 8.

    Rhee PL (2006) Definition and epidemiology of irritable bowel syndrome. Korean J Gastroenterol 47:94–100

    PubMed  Google Scholar 

  9. 9.

    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480–1491

    PubMed  Article  Google Scholar 

  10. 10.

    Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO (1992) Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 33:818–824

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ (2006) Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 130:1538–1551

    PubMed  Article  Google Scholar 

  12. 12.

    Wilson A, Longstreth GF, Knight K, Wong J, Wade S, Chiou CF, Barghout V, Frech F, Ofman JJ (2004) Quality of life in managed care patients with irritable bowel syndrome. Manag Care Interface 17:24–28, 34

    Google Scholar 

  13. 13.

    Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, Frech F, Ofman JJ (2003) Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 98:600–607

    PubMed  Article  Google Scholar 

  14. 14.

    Camilleri M (2006) Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 40:264–269

    PubMed  Article  Google Scholar 

  15. 15.

    Ringel-Kulka T, Ringel Y (2007) Probiotics in irritable bowel syndrome: has the time arrived? Gastroenterology 132:813–816; discussion 816

    PubMed  Article  Google Scholar 

  16. 16.

    Riordan SM, Kim R (2006) Bacterial overgrowth as a cause of irritable bowel syndrome. Curr Opin Gastroenterol 22:669–673

    PubMed  Article  Google Scholar 

  17. 17.

    Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101:326–333

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R (2005) A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22:387–394

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Camilleri M (2006) Is there a role for probiotics in irritable bowel syndrome? Dig Liver Dis 38(Suppl 2):S266–S269

    PubMed  Article  Google Scholar 

Download references

Acknowledgement

Financial support: The authors were supported, in part, by grants from the Seoul Research and Business Development Program (No. 10582).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Poong-Lyul Rhee.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sinn, D.H., Song, J.H., Kim, H.J. et al. Therapeutic Effect of Lactobacillus acidophilus-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome. Dig Dis Sci 53, 2714–2718 (2008). https://doi.org/10.1007/s10620-007-0196-4

Download citation

Keywords

  • Probiotics
  • Irritable bowel syndrome
  • Lactobacillus acidophilus